|
|
|
| Clinical Effect of Terazosin Combined with Tamsulosin in the Treatment of Benign Prostatic Hyperplasia and its Impact of the Level on Serum PSA and TNF- α |
| XU Juan, LI Xiao-xue |
| Ankang Center for Disease Control and Prevention, Ankang 725000, Shaanxi |
|
|
|
|
Abstract 【Objective】To investigate the clinical effect of terazosin combined with tamsulosin on patients with benign prostatic hyperplasia and its effect on the level of the impact of serum PSA and TNF-α. 【Methods】 The clinical data of 102 patients with benign prostatic hyperplasia in our hospital from December 2017 to April 2019 were retrospectively analyzed. According to different treatment schemes, they were divided into observation group (n=50) and control group (n=52). The control group was treated with terazosin, and the observation group was treated with tamsulosin on the basis of the control group. The clinical effect, serum prostate specific antigen (PSA) and tumor necrosis factor-α (TNF)-α were compared between the two groups. The maximum urine flow, residual urine volume and International Prostate Symptom Score (IPSS) were recorded. 【Results】The total effective rate of the observation group was 92.0% (46/50), significantly higher than 86.5% (45/52) of the control group, the difference was statistically significant(χ2=2.8319,P=0.004<0.05).After treatment, the level of serum TNF- αand PSA of the observation group was significantly higher than that of the control group, there was significant difference between the two groups (P<0.05). After treatment, the maximum urine flow and IPSS score of the observation group were significantly higher than those of the control group, and the residual urine volume of the observation group was significantly lower than that of the control group (P<0.05).【Conclusion】 Terazosin combined with tamsulosin can effectively improve the maximum urine flow and residual urine volume of patients with benign prostatic hyperplasia, reduce the level of PSA, and improve the anti-inflammatory immune effect, which is worthy of clinical application.
|
|
Received: 06 June 2019
|
|
|
|
|
|
[1] 张艳红,王少芳,马社君,等.影响前列腺增生合并膀胱过度活动综合征患者术后效果的多因素回归分析[J].中华实验外科杂志,2015,32(6):1303-1305.
[2] 邱敏捷,庞程,田浩,等.经尿道前列腺剜除术治疗老年前列腺增生的疗效[J].中国老年学杂志,2015,28(3):665-667.
[3] 赵力,沈文浩,印苏培,等.经尿道前列腺电切术治疗大体积良性前列腺增生安全性及有效性的回顾性对照研究[J].中华泌尿外科杂志,2015,36(4):299-303.
[4] 王倩,杨胜楠,赵倩茹,等.高龄男性患者前列腺增生与肾功能的相关性研究[J].中华老年医学杂志,2018,37(3):284-287.
[5] 常艳华,王会,李旭东,等.经尿道前列腺扩裂术治疗中年前列腺增生致急性尿潴留的疗效[J].中国微创外科杂志,2018,18(9):819-821.
[6] 吴成璋,李顺.盐酸特拉唑嗪联合非那雄胺片对老年良性前列腺增生患者血清TNF-α及PSA水平的影响[J].中国生化药物杂志,2016,36(4):97-99.
[7] 肖剑,李文钊,张启飞,等.坦索罗辛治疗良性前列腺增生疗效及安全性的 Meta 分析[J].吉林医学,2015,19(10):2104.
[8] 王保营.坦索罗辛治疗前列腺增生的临床疗效及安全性评价[J].中国医药指南,2015,46(18):134.
[9] 辛士永,任小强,张建国,等.坦索罗辛联合索利那新在治疗前列腺增生不同症状阶段伴膀胱过度活动症的疗效[J].中国老年学杂志,2016,36(17):4293-4295.
[10] 苏鹏超,赵继懋,宋健,等.索非那新联合坦索罗辛治疗前列腺增生伴膀胱过度活动症的有效性Meta分析[J].现代泌尿外科杂志,2015,25(11):794-797.
[11] 张前兴,马利英,朱建平,等.坦索罗辛联合托特罗定治疗良性前列腺增生伴膀胱过度活动症的临床研究[J].临床军医杂志,2015,43(1):30-33. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(5): 793-795. |
|
|
|
|
2021, Vol. 38 
